|Bid||6.16 x 800|
|Ask||6.49 x 800|
|Day's Range||5.61 - 6.46|
|52 Week Range||4.01 - 51.60|
|Beta (3Y Monthly)||2.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.42|
Novavax Inc. has suffered yet another major setback in its quest to get its respiratory syncytial virus vaccine to market: European regulators aren’t on board. The Gaithersburg company expects to receive notice that the European Medicines Agency won’t be granting RSV vaccine ResVax a conditional marketing authorization pathway in the European Union, “based on the data package provided under the scientific advice request,” Novavax (NASDAQ: NVAX) disclosed in Securities and Exchange Commission filings Monday.
GAITHERSBURG, Md., Sept. 06, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
Zacks.com featured highlights include: Novavax, The Cooper Companies, Veeco Instruments and Maxar Technologies
A Montgomery County research enterprise is seeking proposals from prospective tenants to lease a manufacturing facility on the Interstate 270 corridor, where there is a dearth of lab space despite a fast-growing biotech industry demanding more of it. The Institute for Bioscience and Biotechnology Research, a venture of the University of Maryland and the National Institute of Standards and Technology, has issued a request for proposals for 9,100 square feet on its Rockville campus at 9600 Gudelsky Drive. The site encompasses a Good Manufacturing Practice, or GMP, suite that complies with Food and Drug Administration requirements.
Novavax, Inc. (NASDAQ:NVAX) has rebounded strongly over the last week, with the share price soaring 89%. But that is...
2019 has been a good year for the stock market. Year-to-date, both the S&P 500 and the Nasdaq are up 15% and 19%, respectively. From an economic perspective, the unemployment levels and interest rates have remained low, which helped boost share prices. That being said, the market isn’t immune to the recent dramas that have unfolded. The ongoing trade war with China and weak global growth have raised red flags among investors that a recession could be on the way, with those fears causing widespread volatility.However, analysts are telling investors not to panic. Wall Street analysts believe that healthcare stocks still represent compelling investment opportunities amid economic uncertainty.Using TipRanks powerful stock screener, we set out to pinpoint three stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, we selected filters for healthcare stocks with a “strong buy” consensus ratings. We also specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target.Now let’s delve into these three top healthcare stocks and see if they really have what it takes to fight off the market flu: Novavax Inc. (NVAX)The first healthcare company on our list develops vaccines that target respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV).Novavax has riled up Wall Street last week with enticing Phase III ResVax trial results. The data presented at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) on August 12 showed that the company's ResVax vaccine was able to protect infants one year after birth from all causes of pneumonia, including RSV associated pneumonia. It also highlighted the fact that protecting infants from the RSV infection can protect infants from contracting an infection from other microbes.Investors have more reasons to be excited about the vaccine maker. On August 5, NVAX reached an agreement with the FDA on its Phase 3 trial design for Nanoflu, its seasonal influenza vaccine for adults 65 years and older. The company also partnered with Catalent Biologics (CTLT) back in June, allowing CTLT to expand its gene therapy footprint with the acquisition of Novavax’s manufacturing assets and capabilities.B.Riley FBR analyst George Zavoico remains bullish on NVAX with a Buy rating, and his $35 price target, which seems like wishful thinking, may get another boost: “Based on these new results and other recent events, we place our price target for Novavax under review as we update our financial model of the company.” (To watch Zavoico's track record, click here)"We do not believe these new, positive results will lead the FDA to reconsider its decision to require another Phase III trial of ResVax by maternal immunization before considering a BLA filing. While we still forecast that the European Medicines Agency (EMA) is likely to agree with the FDA on this point, we would not be surprised if, due partly to these new results, the EMA may decide to allow Novavax to file a marketing authorization application (MAA) for ResVax while also requiring a post-marketing efficacy trial to confirm the results. A decision is expected this fall," Zavoico opined.All in all, the rest of the Street mirrors the analysts’ bullish sentiment. NVAX has a ‘Strong Buy’ analyst consensus and a $29.88 average price target, implying ~281% upside potential from current levels. (See NVAX’s price targets and analyst ratings on TipRanks) Amarin Corporation (AMRN)It’s no secret that Wall Street analysts like Amarin stock. It has a ‘Strong Buy’ analyst consensus and a ~$32 average price target, suggesting over 100% upside potential from current levels. (See AMRN’s price targets and analyst ratings on TipRanks)Investors were caught by surprise recently after Amarin announced the FDA’s notice of plans to hold an advisory committee (AdCom) on the sNDA for its Vascepa drug.4-star Roth Capital analyst Yasmeen Rahimi argues that the AdCom might work in AMRN’s favor.While the news comes as a shock given how close AMRN is to its September 28 priority-review PDUFA for Vascepa, management stated in May that they believed an AdCom was likely as they are seeking a Vascepa label extension. As such, the AdCom gives AMRN a platform to defend its label extension as well as highlight Vascepa’s ability to reduce cardiovascular related events and deaths, its superior safety and its support from the medical community.“AdCom allows for Vascepa discussion in a public forum, increasing awareness and transparency on key issues, and puts all this info just a click away for potential future Vascepa-prescribers to find and digest,” Rahimi opined, as she reiterates her Buy rating and $31 price target on Amarin stock."In totality, we believe AMRN is primed to make a strong case to the FDA and can turn this AdCom into a highlight reel of the CV benefits Vascepa offers patients," the analyst concluded. (To watch Rahimi's track record, click here) Zynerba Pharmaceuticals (ZYNE)Zynerba develops innovative therapies to treat Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).Investment firm Canaccord Genuity has hosted Zynerba at its annual growth conference the day after its second quarter earnings release in which the company altered some timelines for its data readouts. Lead analyst Sumant Kulkarni believes the company is still cautiously optimistic regarding its Zygel (cannabidiol gel) in Fragile X syndrome (FXS). While its Zygel trial enrollment continues, the company hasn’t provided an end date for enrollment. ZYNE does remain confident that Zygel use in DEE treatment can deliver an adequate dose of CBD via the transdermal route.The analyst points out that an Epidiolex CBD solution for Lennox-Gastaut/Dravet syndromesits has already been released by its competitor, GW Pharmaceuticals (GWPH). Not to mention GWPH’s market cap is $5 billion versus ZYNE’s $250 million. However, Kulkarni argues that this disparity represents a unique buying opportunity.Based on all of the above factors, Kulkarni reiterates his Buy rating and $18 price target on ZYNE stock, which implies about 60% upside from current levels.Kulkarni is certainly not the first analyst with an optimistic outlook for the biotech firm, as TipRanks analytics showcasing ZYNE stock as a Strong Buy. With an average price target of $22, analysts are predicting an upside of nearly 100%. In total, the stock has received 4 'buy' ratings in the last three months. (See ZYNE’s price targets and analyst ratings on TipRanks)
We’ve used TipRanks’ Top Analysts Stocks tool to search our database for the best stocks to buy in today’s highly volatile markets. While looking for investments with strong prospects for high growth and returns, we found companies with support from some of Wall Street’s top analysts.So, let’s get to it. Here are four stocks that analysts believe have potential to bring in high profits for investors, even as recession fears mount. All four show indications of being undervalued in prevailing market conditions and show a high upside.Amazon Stock Could Surge Back to $2,300E-commerce titan Amazon (AMZN) is down more than 12% from its peak above $2,000 in the first half of July. The slip does not indicate anything fundamentally wrong with the stock, however; for the most part, Amazon shares have simply been caught up in the general selling that has characterized recent weeks.The most important thing to realize about Amazon is that, despite the 1.15% earnings miss in the last quarter, the company showed a strong revenue beat; the $63.4 billion was higher than the $62.5 billion expected, 16.8% higher than Q1, and 20% higher than the year-ago quarter. The revenue gains come after Amazon spent $800 million during Q2 streamlining warehouse services and product delivery as part of a successful effort to ensure standard one-day shipping for all Prime customers. In short, Amazon prioritized sales growth over margins, accepting lower net earnings as the near-term cost of higher gross revenues.As investors digest that, the stock is likely to recover. 4-star analyst Scott Mushkin of Wolfe Research writes of Amazon’s Q2 and future prospects: “AMZN’s quarter clearly demonstrated that there is a demand elasticity for faster shipping, and the difference between 1-day and 2day can be significant for customers. Our research suggests that this is particularly true for faster-turning consumable items, which represents a relatively underpenetrated $1.5 trillion market and a meaningful area of long-term growth for Amazon… AMZN has outperformed the market so far this year and our research suggests that it should continue to outperform for the remainder of 2019.”In line with this bullish long-term view, Mushkin sets a Buy rating on AMZN shares, with a price target of $2,300, suggesting an upside of 30%. (To watch Mushkin's track record, click here) Mushkin's outlook matches well with Amazon’s consensus rating, a Strong Buy based on a unanimous 30 buys, and an average price target of $2,283. Shares of Amazon are currently priced at $1,762, so the stock has an upside potential of 29%. (See AMZN's price targets and analyst ratings on TipRanks)Monetization Potential Trumps Privacy Issues for FacebookOur second go-to stock is another tech giant, Facebook, Inc. (FB). The social media leader and innovator has had its ups and downs – the company’s issues with user privacy protections hardly need an introduction anymore – but it is still up 37% year-to-date, has shown positive user growth trends, and predicts revenue growth in the 15% range going forward. Even better, gross margins are stabilizing around 40%, and healthy number for any company.Despite the privacy issues, Facebook’s apps remain popular. Instagram and other the other digital products in Facebook’s ecosystem continue to attract users, and ad revenue naturally follows. Facebook is pushing ahead with plans to increase monetization of Messenger, WhatsApp, and Stories, and the Libra initiative announced in June signals a drive toward both blockchain currency and e-commerce.Susquehanna’s 5-star analyst Shyam Patil reiterates his Buy rating on Facebook, and raises his price target to $245, saying, “We still see FB as a reliable high-teens/low-20s percent top-line grower with potentially faster bottom-line growth over the next several years. Catalysts include continued strong quarterly performance, as the key drivers continue to play out, and successful product launches and monetization.”Patil’s price target on FB suggests a 36% upside to the stock. Of the stock’s potential, Patil says, “FB is a must-own for the second half.” (To watch Patil's track record, click here)Facebook’s analyst consensus rating, Strong Buy, is based on 33 buys and 3 holds. The stock is trading for $179, and the average price target of $234 implies an upside of 30%. (See FB's price targets and analyst ratings on TipRanks) Popular Trucks and SUVs Keep GM in the BlackGeneral Motors (GM), the largest of Detroit’s Big 3 automakers, delivered a happy surprise in Q2 by beating both revenue and earnings expectations. Dhivya Suryadevara, GM’s CFO, said, “We had a solid second quarter and expect the second half of the year to be stronger than the first half… based on our strong full-size truck rollout, other key launches and ongoing cost savings.”In addition to a good Q2, management is bullish about prospects going forward. GM expects sales to improve in 2H19 on a strong mix of pickup truck and SUVs, along with high-end CUVs, and predicts a full-year EPS between $6.50 and $7, an improvement from 2018’s full year earnings of $6.54.Writing from Barclay’s, analyst Brian Johnson says, “GM is making considerable progress in securing a role in a future world of Disruptive Mobility (shared autonomous driving)… With the rest of world stalled, and no Europe exposure to agonize over, the central engine of GM earnings power remains GMNA and within that its pickup, SUV and to a lesser extent CUV products. For 2019…, in pickups/SUVs, strength from a full year of ½ tons, a half year of ¾ tons more than offsets the headwind from the outdoing SUVs.”Johnson raised his price target on GM stock by 6%, from $48 to $51. This suggests an upside of 37% for the automaker, slightly higher than the stock’s 34% upside based on the average price target of $50. (To watch Johnson's track record, click here) The stock is selling for $37, and the analyst consensus rating of Strong Buy is based on 7 buys and 1 hold assigned in the last three months. (See GM's price targets and analyst ratings on TipRanks)Sky-High Potential Makes Novavax AttractiveThe fourth stock we’re looking at here, Novavax, Inc. (NVAX), is a biotech in the vaccine business. The company’s main product is a vaccine for respiratory syncytial virus, specially, a vaccine to protect newborn infants from the virus and the associated lung disease. The new vaccine, ResVax, failed its first Phase III trial, leading to a sharp drop in the company’s share price. Novavax shares skyrocketed whopping 40% yesterday, and there’s just one reason why: Yesterday morning, investment banker H.C. Wainwright announced a big price target upgrade on NVAX. The reason? "We think Novavax keeps winning with NanoFlu." In line with his upbeat outlook, H.C. Wainwright's Vernon Bernardino gives NVAX a $17 price target (up from $10), indicating confidence in an impressive 180% upside. (To watch Bernardino's track record, click here) Bernardino, writing of Novavax’s future prospects, says, “We made no changes to our models, as we previously believed the near-term focus would be completing an additional Phase 3 ResVax study… We look for share price appreciation to allow successful financings in 2020-2021, positioning Novavax to independently launch commercial NanoFlu worldwide. We think NanoFlu can achieve $1.7B in annual sales by 2028.” Like many biotech firms, Novavax combines high upside with high risk. The stock is selling for just $6 per share – but the average price target is $29, giving the stock an eye-opening upside potential of 394%. The analyst consensus rating of Strong Buy is based on 4 buys assigned in recent days, after the company announced the second Phase III trial for ResVax.
A new analysis of the company’s phase 3 study for ResVax shows the candidate effectively diminished pneumonia cases in infants tied to RSV, a respiratory illness in newborns.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down ...
Novavax, Inc. (NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the presentation of new data from the company’s Prepare™ trial, a global Phase 3 clinical trial of ResVax™, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine.
GAITHERSBURG, Md., Aug. 08, 2019 -- Novavax, Inc. (NASDAQ: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today.
Novavax (NVAX) delivered earnings and revenue surprises of -4.97% and -4.98%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Novavax has the green light to start a late-stage clinical trial for its seasonal flu vaccine, less than six months after a phase 3 trial for its RSV vaccine failed and sent the company’s future into question.
Agreement with the FDA on Phase 3 non-inferiority immunogenicity study design for NanoFlu™NanoFlu pivotal Phase 3 clinical trial expected to initiate in the third quarter of.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on ...
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it received input from the U.S. Food and Drug Administration (FDA) on its End-of Phase 2 questions and has reached agreement on its Phase 3 trial design for NanoFlu™, its adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for older adults aged 65 and over. Novavax plans to initiate the pivotal Phase 3 clinical trial of NanoFlu in the fall of 2019, with top-line clinical data expected in the first quarter of 2020.